The Efficacy of azithromycin in the treatment of COVID-19

Authors

DOI:

https://doi.org/10.33448/rsd-v13i3.45106

Keywords:

Serodiagnosis of COVID-19; 2019-nCoV; Severe acute respiratory syndrome coronavirus 2; Pandemic; Azithromycin; Long-term adverse effects; Antibiotic bacterial resistance.

Abstract

COVID-19, caused by the SARS-CoV-2 virus, is a severe acute respiratory disease with high transmissibility. The pandemic originated in China in 2019 and resulted in symptoms ranging from mild to severe, particularly affecting individuals with comorbidities. The virus utilizes the "spike" protein to enter human cells, initiating a replication process that can lead to widespread infection in the body. The pandemic reached Brazil in 2020, prompting various governmental actions. With increasing cases, searches for treatments, including the use of azithromycin, became common. Azithromycin, an antibiotic, had its efficacy in COVID-19 debated, especially when combined with hydroxychloroquine. Divergent studies emphasized the need for caution due to potential adverse effects and bacterial resistance. This study aims to report and critically evaluate the effectiveness and safety of azithromycin in treating COVID-19, providing evidence-based guidance.

References

Almeida, A. L., da Silva Araújo, A. C. L., & da Costa, G. K. M. (2022). Consequências do uso irracional de azitromicina durante a pandemia de COVID-19. Research, Society and Development, 11(16), e512111638771-e512111638771.

Brasil. (2022). Dois anos do primeiro caso de coronavírus no Brasil. Rádio Senado. Senado Federal. https://www12.senado.leg.br/radio/1/noticia/2022/02/23/dois-anos-do-primeiro-caso-de-coronavirus-no-brasil“

Brasil. (2023). Como se proteger. Ministério da Saúde. https://www.gov.br/saude/pt-br/assuntos/coronavirus/como-se-proteger“.

Brown, C. M., Vostok, J., Johnson, H., et al. (2023). Outcomes of COVID-19 in patients treated with hydroxychloroquine or azithromycin in Veterans Health Administration hospitals. Open Forum Infectious Diseases. 10 (1), ofab501.

Chacón Acevedo, K., Pinzón, C., Barrera, A., Low Padilla, E., & Yomayusa González, N. (2020). Eficacia y seguridad de la cloroquina, la hidroxicloroquina y la azitromicina en pacientes con COVID-19. Resumen de evidência. Revista Colombiana de Nefrología, 7, 21-41.

Cachoni, A. C., Cadari, M. B., Vieira, G., Sant'Ana, A. P., Zorzi-Colete, J., Neto, J. L. T., & Mulinari-Santos, G. (2022). Perfil de Segurança e Eficácia Clínica da Azitromicina no Tratamento da COVID-19: Revisão da Literatura. Archives of Health Investigation, 11(2), 332-336.

Campos, M. R. et al. (2023). Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública. 36 (11), e00148920. https://doi.org/10.1590/0102-311X00148920

Echeverría-Esn al, D., Martin-Ontiyuelo, C., Navarrete-Rouco, M. E., De-Antonio Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2021). Azithromycin in the treatment of COVID-19: a review. Expert review of anti-infective therapy, 19(2), 147–163. https://doi.org/10.1080/14787210.2020.1813024

Fiocruz. (2022, 18 de janeiro). Vacinação contra a Covid-19 no Brasil completa um ano. *Bio-Manguinhos*. https://portal.fiocruz.br/noticia/vacinacao-contra-covid-19-no-brasil-completa-um-ano#:~:text=Compartilhar%3A,a%20Covid%2D19%20no%20Brasil.

Freires, M. S., & Rodrigues Junior, O. M. (2022). Análise da automedicação durante a pandemia do novo coronavírus: um olhar sobre a azitromicina. Research, Society and Development, 11(1), e31611125035. https://doi.org/10.33448/rsd-v11i1.25035

Gautret, P., Lagier, J. C., Parola, P., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949.

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022). Mechanisms of SARS-CoV-2 entry into cells. Nature reviews. Molecular cell biology, 23(1), 3–20. https://doi.org/10.1038/s41580-021-00418-x

Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents, 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

Lana, R. M. et al. (2023). Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cadernos de Saúde Pública [online], 36(3), e00019620. https://doi.org/10.1590/0102-311X00019620

Lima Souza, L., Magon Sá, A., & Martelato Gimenez, F. V. (2023). O uso da azitromicina no tratamento da covid-19: uma revisão de literatura. Revista Foco (Interdisciplinary Studies Journal), 16(2).

Moura, J. M. (2021). Indicação e uso de azitromicina no tratamento do COVID-19: revisão da literatura/Indication of azithromycin in the treatment of COVID-19: literature review. Brazilian Journal of Development, 7(6), 56547-56556.

OPAS. (2020). Histórico da Pandemia COVID-19. Organização Pan-Americana da Saúde (OPAS). https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19

Ray, W. A., Murray, K. T., & Hall, K. (2022). Azithromycin and the Risk of Cardiovascular Death. New England Journal of Medicine, 366(20), 1881-1890.

RECOVERY Collaborative Group. (2021). Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397(10274), 605-612.

Reis, F., Junior, J. D. J. R., & Dominato, A. A. G. (2023). Uso de cloroquina, azitromicina e ivermectina durante a pandemia da COVID-19: Uma revisão integrativa. Research, Society and Development, 12(13), e44121344225-e44121344225.

Souza-Silva, M. V. R., Pereira, D. N., Pires, M. C., Vasconcelos, I. M., Schwarzbold, A. V., Vasconcelos, D. H., Pereira, E. C., Manenti, E. R. F., Costa, F. R., Aguiar, F. C., Anschau, F., Bartolazzi, F., Nascimento, G. F., Vianna, H. R., Batista, J. L., Machado-Rugolo, J., Ruschel, K. B., Ferreira, M. A. P., Oliveira, L. S., Menezes, L. S. M., Ziegelmann, P. K., Tofani, M. G. T., Bicalho, M. A. C., Nogueira, M. C. A., Guimarães-Júnior, M. H., Aguiar, R. L. O., Rios, D. R. A., Polanczyk, C. A., & Marcolino, M. S. (2023). Dados de Vida Real sobre o Uso da Hidroxicloroquina ou da Cloroquina Combinadas ou Não à Azitromicina em Pacientes com Covid-19: Uma Análise Retrospectiva no Brasil. Arquivos Brasileiros de Cardiologia, 120(9), e20220935.

Wang, L. S., Wang, Y. R., Ye, D. W. & Liu, Q. Q. (2020). A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. International Journal of Antimicrobial Agents. https://doi.org/10.1016/j.ijantimicag.2020.105924

Published

13/03/2024

How to Cite

GOMES, K. F. de L. .; MAIA NETO, J. R. .; REMOR, G. L. .; ESPINHEIRO, M. G. .; DINIZ, I. G. .; GUIMARÃES, M. C. M. . The Efficacy of azithromycin in the treatment of COVID-19. Research, Society and Development, [S. l.], v. 13, n. 3, p. e3713345106, 2024. DOI: 10.33448/rsd-v13i3.45106. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/45106. Acesso em: 15 jun. 2024.

Issue

Section

Health Sciences